ZBP1 PROTAC-1

ZBP1 PROTAC-1 (C-PROTAC) forms stable covalent bonds with nucleophilic amino acid groups on the Zα domain of purified ZBP1, enabling specific labeling of the wild-type protein that is reduced in Zα domain mutants lacking these nucleophilic groups^[1].
ZBP1 PROTAC-1 specifically labels purified ZBP1 via its aptamer-guided targeting, showing minimal off-target labeling of purified BSA^[1].
ZBP1 PROTAC-1 (12.5-200 nM; 0-48 h) potently and selectively degrades ZBP1 in cells via the proteasome system, with a DC₅₀ of 25.69 nM and a ZBP1 half-life of 17.03 h, showing superior efficacy over non-covalent traditional PROTAC^[1].
ZBP1 PROTAC-1 (12.5-200 nM) specifically inhibits ZBP1-mediated necroptotic signaling in CBL0137-treated cells by reducing RIPK3 and MLKL phosphorylation, without impacting apoptosis-related Caspase-8 expression^[1].
ZBP1 PROTAC-1 (100 nM) effectively degrades virus-upregulated ZBP1 in H1N1-infected cells, requiring both its aptamer and NASA-VHL ligand modules for activity^[1].
ZBP1 PROTAC-1 (100 nM) restores viability of H1N1-infected cells to 95.8%, demonstrating superior therapeutic efficacy over traditional PROTAC^[1].
ZBP1 PROTAC-1 (100 nM) effectively restores cellular proliferation and activity in H1N1-infected cells, with superior efficacy over traditional PROTAC^[1].
ZBP1 PROTAC-1 (100 nM) suppresses the H1N1-induced inflammatory response in cells by reducing mRNA levels of proinflammatory cytokines IL-18, IL-1β, IL-6, TNF-α, and IFN-β^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.